US010266578B2

(12) **United States Patent**
Dubowchik et al.

(10) **Patent No.: US 10,266,578 B2**
(45) **Date of Patent: Apr. 23, 2019**

(54) **MODIFIED RELAXIN POLYPEPTIDES COMPRISING A PHARMACOKINETIC ENHANCER AND USES THEREOF**

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY**, Princeton, NJ (US)

(72) Inventors: **Gene M. Dubowchik**, Middlefield, CT (US); **Olafur S. Gudmundsson**, West Windsor, NJ (US); **Xiaojun Han**, Cheshire, CT (US); **R. Michael Lawrence**, Yardley, PA (US); **Dasa Lipovsek**, Pepperell, MA (US); **Cort S. Madsen**, West Windsor, NJ (US); **Claudio Mapelli**, Linden, NJ (US); **Paul E. Morin**, Pennington, NJ (US); **Michael C. Myers**, Newtown, PA (US)

(73) Assignee: **Bristol-Myers Squibb Company**, Princeton, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **15/891,492**

(22) Filed: **Feb. 8, 2018**

(65) **Prior Publication Data**

US 2018/0222960 A1 Aug. 9, 2018

Related U.S. Application Data

(60) Provisional application No. 62/627,411, filed on Feb. 7, 2018, provisional application No. 62/456,161, filed on Feb. 8, 2017.

(51) **Int. Cl.**

A61K 38/18	(2006.01)
C07K 14/64	(2006.01)
C07K 1/107	(2006.01)
A61K 38/00	(2006.01)
A61K 47/64	(2017.01)
A61P 9/00	(2006.01)
A61K 45/06	(2006.01)

(52) **U.S. Cl.**

CPC ***C07K 14/64*** (2013.01); ***C07K 1/1077*** (2013.01); *A61K 38/00* (2013.01); *A61K 45/06* (2013.01); *A61K 47/64* (2017.08); *A61P 9/00* (2018.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,773,919	A	11/1973	Boswell et al.
4,289,872	A	9/1981	Denkewalter et al.
4,412,989	A	11/1983	Iwashita et al.
4,414,148	A	11/1983	Jansen et al.
4,485,045	A	11/1984	Regen
4,511,502	A	4/1985	Builder et al.
4,511,503	A	4/1985	Olson et al.
4,512,922	A	4/1985	Jones et al.
4,544,545	A	10/1985	Ryan et al.
4,551,433	A	11/1985	Deboer
4,569,789	A	2/1986	Blattler et al.
4,619,794	A	10/1986	Hauser
4,659,839	A	4/1987	Nicolotti et al.
4,670,417	A	6/1987	Iwasaki et al.
4,671,958	A	6/1987	Rodwell et al.
4,680,338	A	7/1987	Sundoro
4,689,406	A	8/1987	Banks et al.
4,699,784	A	10/1987	Shih et al.
4,738,921	A	4/1988	Belagaje et al.
4,755,465	A	7/1988	Gray et al.
4,837,148	A	6/1989	Cregg
4,859,600	A	8/1989	Gray et al.
4,876,197	A	10/1989	Burke et al.
4,880,734	A	11/1989	Burke et al.
4,902,502	A	2/1990	Nitecki et al.
4,904,584	A	2/1990	Shaw
4,929,555	A	5/1990	Cregg et al.
5,021,234	A	6/1991	Ehrenfeld
5,089,398	A	2/1992	Rosenberg et al.
5,122,614	A	6/1992	Zalipsky
5,145,962	A	9/1992	Hudson et al.
5,162,601	A	11/1992	Slightom
5,219,564	A	6/1993	Zalipsky et al.
5,229,490	A	7/1993	Tam
5,231,178	A	7/1993	Holtz et al.
5,252,714	A	10/1993	Harris et al.

(Continued)

FOREIGN PATENT DOCUMENTS

CA	2300362	2/1999
CA	2707840	2/2009

(Continued)

OTHER PUBLICATIONS

Ghosh et al.; "Serelaxin in acute heart failure: Most recent update on clinical and preclinical evidence." *Cardiovascular therapeutics* 351 (2017): 55-63.

Hossain et al., "The minimal active structure of human relaxin-2." *Journal of Biological Chemistry* 286.43 (2011): 37555-37565.

Chen et al., "Fusion protein linkers: property, design and functionality." *Advanced drug delivery reviews* 65.10 (2013): 1357-1369.

Zhongming Tang, "Biotechnology Drugs—Introduction and Practical Handbook", Chemical Industry Press, Jan. 2008.

(Continued)

Primary Examiner — Christine J Saoud

(74) *Attorney, Agent, or Firm* — Robin L. Teskin; LeClairRyan PLLC

(57) **ABSTRACT**

The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.

30 Claims, 5 Drawing Sheets

Specification includes a Sequence Listing.